Answers are grounded in this paper and cite their sources.
Immune checkpoint inhibitors are drugs that interfere with tumor escape responses. Some members of this class are already approved, and expected to be blockbusters in the future. Many companies have developed patent activities in this field. This article focuses on the patent landscape, and discusses key players and cases related to immune checkpoint inhibitors.
No takes yet. Share an insight, caveat, or question.
Ulrich Storz (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: